[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-soft-tissue-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-soft-tissue-sarcoma":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100201442",false,"NCT01898663","DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ\u002FⅡ Study","Inclusion Criteria:\n\n* Consistent with the diagnosis of AML\n* Age≥18 years at time of consent\n* KPS(Karnofsky Performance Scale) ≥70\n* Patient's written informed consent\n* No steroid therapy within 4 weeks of first DC vaccination\n* Stable disease, complete response and partial response(WHO, RECIST)\n* Predicted survival≥3 months\n\nExclusion Criteria:\n\n* Serious dysfunction of vital organs(heart, liver or kidney)\n* Received organ transplantation\n* Patients with other malignancies or brain metastases\n* History of autoimmune diseases\n* Pregnant and breast-feeding patient\n* Active or chronic infectious diseases\n* History of allergy or hypersensitivity to study product excipients\n* Currently participating in another clinical trial\n* Received chemotherapy, radiotherapy, immune inhibitor (such as corticosteroid) or other immunotherapy (such as vaccine) during prior 4 weeks\n* Unfit for participating in this clinical trial in investigators' opinions","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","The aim of this Phase Ⅰ\u002FⅡ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.",[26],"High-risk Soft Tissue Sarcoma","RECRUITING","2024-06-28",{"date":30,"type":31},"2024-07-01","ACTUAL",{"date":33,"type":4},"2013-06",{"date":35,"type":19},"2024-12-30",{"name":37,"class":38},"Affiliated Hospital to Academy of Military Medical Sciences","OTHER",""]